HERVolution Publishes Translational Tumor Data Supporting HERV-K as an "Off-the-Shelf" Cancer Vaccine Target
Peer-reviewed study finds HERV-K antigen-coding sequences expressed in all 207 advanced non-small cell lung cancer tumors analyzed, and reports that lung cancer cell lines depend on HERV-K for growth and survival COPENHAGEN, Denmark and NEW YORK, Nov. 5, 2026 /PRNewswire/ -- HERVolution...
Covered in this story
Call it yourself
No calls on $NOV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on NOV →Dalsna Finance is currently tracking 89 stories mentioning NOV, the earliest published 16 Dec 2025.
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.